Business Case

Lifecycle planning for a pipeline solid cancer therapy asset

Our client, a large multi-national biopharma company, was looking to commercialize their solid tumor asset and wanted to create a lifecycle plan for the next 10 years. LSC was able to synthesize the current and future cancer landscape specific to this asset, establish a lifecycle strategy, and develop a data generation plan to ensure asset relevance for 10+ years. The projected outcome allowed the client to gain alignment on clinical development investments and initiate multiple studies.